Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aripiprazole.

Jane K McGavin1, Karen L Goa

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand.

CNS Drugs
|October 18, 2002
PubMed
Summary
This summary is machine-generated.

Aripiprazole, a novel antipsychotic, demonstrated efficacy comparable to haloperidol and risperidone in treating schizophrenia relapse. It showed faster improvement in negative symptoms and a lower incidence of side effects like extrapyramidal symptoms and prolactin increase.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017
Same author

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Drugs·2017
Same author

Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.

Treatments in endocrinology·2005
Same author

Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.

Treatments in endocrinology·2005
Same author

Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

Treatments in endocrinology·2005
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Aripiprazole represents a new class of atypical antipsychotics, a quinolinone derivative.
  • It exhibits unique partial agonist activity at dopamine D(2) and serotonin 5-HT(1A) receptors, alongside 5-HT(2A) receptor antagonism.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of aripiprazole in patients with schizophrenia and schizoaffective disorder.
  • To compare aripiprazole's effectiveness against established treatments like haloperidol and risperidone, as well as placebo.

Main Methods:

  • Conducted well-designed, 4-week, placebo-controlled trials comparing aripiprazole (15-30 mg/day) with haloperidol (10 mg/day) and risperidone (6 mg/day).
  • Extended trials included a 26-week study in stable chronic schizophrenia and a 52-week study in acute relapsing disease.

Related Experiment Videos

  • Assessed efficacy based on symptom improvement, time to treatment failure, and incidence of adverse events including extrapyramidal symptoms and QTc prolongation.

    • Main Results:

    • Aripiprazole showed efficacy at week 1, sustained throughout study periods, comparable to haloperidol and risperidone in acute relapse.
    • Negative symptoms improved earlier with aripiprazole compared to risperidone.
    • Aripiprazole was superior to placebo in chronic schizophrenia and demonstrated superiority in ameliorating negative and depressive symptoms over haloperidol in a long-term trial, with similar rates of extrapyramidal symptoms and lower prolactin elevation compared to haloperidol and risperidone.

    Conclusions:

    • Aripiprazole is an effective treatment for acute relapse and stable chronic schizophrenia, offering benefits in negative and depressive symptoms.
    • Its side effect profile, including extrapyramidal symptoms and prolactin levels, is favorable compared to haloperidol and risperidone.
    • Aripiprazole's unique receptor activity contributes to its efficacy and tolerability in managing psychotic disorders.